Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data

BACKGROUND: Treatment of patients with type 2 diabetes mellitus (T2DM) and a history of cardiovascular (CV) disease or CV risk factors may present clinical challenges due to the presence of comorbid conditions and the use of concomitant medications. The sodium glucose co-transporter 2 inhibitor, can...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Michael J., Merton, Katherine, Vijapurkar, Ujjwala, Yee, Jacqueline, Qiu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361783/
https://www.ncbi.nlm.nih.gov/pubmed/28327140
http://dx.doi.org/10.1186/s12933-017-0517-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361783/
https://www.ncbi.nlm.nih.gov/pubmed/28327140
http://dx.doi.org/10.1186/s12933-017-0517-7

Ejemplares similares